1. Home
  2. EYPT vs RPAY Comparison

EYPT vs RPAY Comparison

Compare EYPT & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • RPAY
  • Stock Information
  • Founded
  • EYPT 1987
  • RPAY 2006
  • Country
  • EYPT United States
  • RPAY United States
  • Employees
  • EYPT N/A
  • RPAY N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • RPAY Business Services
  • Sector
  • EYPT Industrials
  • RPAY Consumer Discretionary
  • Exchange
  • EYPT Nasdaq
  • RPAY Nasdaq
  • Market Cap
  • EYPT 594.5M
  • RPAY 665.4M
  • IPO Year
  • EYPT 2005
  • RPAY N/A
  • Fundamental
  • Price
  • EYPT $7.48
  • RPAY $7.37
  • Analyst Decision
  • EYPT Strong Buy
  • RPAY Strong Buy
  • Analyst Count
  • EYPT 8
  • RPAY 6
  • Target Price
  • EYPT $25.71
  • RPAY $12.33
  • AVG Volume (30 Days)
  • EYPT 922.9K
  • RPAY 541.0K
  • Earning Date
  • EYPT 03-06-2025
  • RPAY 02-27-2025
  • Dividend Yield
  • EYPT N/A
  • RPAY N/A
  • EPS Growth
  • EYPT N/A
  • RPAY N/A
  • EPS
  • EYPT N/A
  • RPAY N/A
  • Revenue
  • EYPT $45,713,000.00
  • RPAY $310,758,000.00
  • Revenue This Year
  • EYPT N/A
  • RPAY $9.03
  • Revenue Next Year
  • EYPT N/A
  • RPAY $5.59
  • P/E Ratio
  • EYPT N/A
  • RPAY N/A
  • Revenue Growth
  • EYPT 7.50
  • RPAY 5.95
  • 52 Week Low
  • EYPT $6.90
  • RPAY $7.04
  • 52 Week High
  • EYPT $30.99
  • RPAY $11.27
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 44.49
  • RPAY 38.61
  • Support Level
  • EYPT $7.15
  • RPAY $7.15
  • Resistance Level
  • EYPT $8.25
  • RPAY $7.67
  • Average True Range (ATR)
  • EYPT 0.66
  • RPAY 0.21
  • MACD
  • EYPT -0.01
  • RPAY -0.01
  • Stochastic Oscillator
  • EYPT 22.01
  • RPAY 30.14

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About RPAY Repay Holdings Corporation

Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segment, Consumer Payment and Business Payments.

Share on Social Networks: